Literature DB >> 11252351

Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation.

N Kato1.   

Abstract

Hepatitis C virus (HCV) is the major etiologic agent of non-A, non-B hepatitis. HCV infection frequently causes chronic hepatitis, which progresses to liver cirrhosis and hepatocellular carcinoma. Since the discovery of HCV in 1989, a large number of genetic analyses of HCV have been reported, and the viral genome structure has been elucidated. An enveloped virus, HCV belongs to the family Flaviviridae, whose genome consists of a positive-stranded RNA molecule of about 9.6 kilobases and encodes a large polyprotein precursor (about 3000 amino acids). This precursor protein is cleaved by the host and viral proteinase to generate at least 10 proteins: the core, envelope 1 (E1), E2, p7, nonstructural (NS) 2, NS3, NS4A, NS4B, NS5A, and NS5B. These HCV proteins not only function in viral replication but also affect a variety of cellular functions. HCV has been found to have remarkable genetic heterogeneity. To date, more than 30 HCV genotypes have been identified worldwide. Furthermore, HCV may show quasispecies distribution in an infected individual. These findings may have important implications in diagnosis, pathogenesis, treatment, and vaccine development. The hypervariable region 1 found within the envelope E2 protein was shown to be a major site for the genetic evolution of HCV after the onset of hepatitis, and might be involved in escape from the host immunesurveillance system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11252351     DOI: 10.1089/omi.1.2000.5.129

Source DB:  PubMed          Journal:  Microb Comp Genomics        ISSN: 1090-6592


  40 in total

1.  Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases.

Authors:  Jung-Ho Park; Yoshihiro Yamaguchi; Masayori Inouye
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

2.  Genetic Diversity of Hepatitis C Virus Among Blood Donors and Patients with Clinical Hepatitis in Ibadan, Nigeria.

Authors:  J A Shenge; G N Odaibo; D O Olaleye
Journal:  Arch Basic Appl Med       Date:  2018-02

Review 3.  Hepatitis C virus infection and insulin resistance.

Authors:  Sandip K Bose; Ranjit Ray
Journal:  World J Diabetes       Date:  2014-02-15

4.  Functional implications of mitochondrial reactive oxygen species generated by oncogenic viruses.

Authors:  Young Bong Choi; Edward William Harhaj
Journal:  Front Biol (Beijing)       Date:  2014-12

5.  Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.

Authors:  Yoichi Kimura; Toshifumi Gushima; Sharad Rawale; Pravin Kaumaya; Christopher M Walker
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

Review 7.  Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

8.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Impact of all oral anti-hepatitis C virus therapy: A meta-analysis.

Authors:  Siddharth Bansal; Ashwani K Singal; Brendan M McGuire; Bhupinder S Anand
Journal:  World J Hepatol       Date:  2015-04-18

10.  The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.

Authors:  Phillip S Pang; Paul J Planet; Jeffrey S Glenn
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.